Abstract
Purpose
To investigate whether pan-retinal photocoagulation (PRP) affects vitreous levels of cytokines and macular thickening in patients with high-risk proliferative diabetic retinopathy (PDR).
Methods
Fourteen patients with bilateral high-risk PDR—which requires pars plana vitrectomy (PPV)—but without a history of retinal photocoagulation participated in this study. Before PPV, one eye received PRP, and the other eye did not. The concentrations of cytokines of vascular endothelial growth factor (VEGF), stromal derived factor-1 (SDF-1), interleukin-6 (IL-6) and regulated upon activation, normal T-cell expressed and secreted (RANTES) were measured in each vitreous sample obtained at PPV. Macular thickness obtained by optical coherence tomography was also monitored during clinical course.
Results
After the PRP, macular thickness in PRP-pretreated eye showed temporal increase. Vitreous levels of IL-6 and RANTES in PRP pre-treated eye were significantly higher than levels in control eyes (p = 0.013, p = 0.033). Although macular thickness in control was correlated to vitreous levels of VEGF and IL-6 (p = 0.022, p = 0.003), that in PRP-pretreated eye was closely correlated to IL-6 and RANTES (p = 0.002, p = 0.011). After the PPV, macular thickness in both eye groups improved, and there was no significant difference between both eye groups 3 months after the PPV.
Conclusions
In patients with high-risk PDR, PRP cause temporal worsening of macular edema linked with pro-inflammatory cytokines of IL-6 and RANTES, but not with VEGF and SDF-1. Thus, PRP-induced macular edema was caused by inflammation, while visual prognosis after PPV was not influenced by pretreatment of PRP.
Similar content being viewed by others
References
Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE et al (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480–1487
Early Treatment Diabetic Retinopathy Study Research Group (1991) Early photocoagulation for diabetic retinopathy, ETDRS report number 9. Ophthalmology 98:766–785
Early Treatment Diabetic Retinopathy Study Research Group (1991) Early treatment diabetic retinopathy study design and baseline patient characteristics, ETDRS report number 7. Ophthalmology 98:741–756
Shimura M, Yasuda K, Nakazawa T, Kano T, Ota S, Tamai M (2003) Quantifying alterations of macular thickness before and after pan-retinal photocoagulation in patients with severe diabetic retinopathy and good vision. Ophthalmology 110:2386–2394
Shimura M, Yasuda K, Nakazawa T, Tamai M (2005) Visual dysfunction after panretinal photocoagulation in patients with severe diabetic retinopathy and good vision. Am J Ophthalmol 140:8–15
Shimura M, Yasuda K, Shiono T (2006) Posterior subtenon injection of triamcinolone acetonide prevents pan-retinal photocoagulation-induced visual dysfunction in patients with severe diabetic retinopathy and good vision. Ophthalmology 113:381–387
MacMeel JW, Trempe CL, Franks EB (1977) Diabetic maculopathy. Trans Am Acad Ophthalmol Otolaryngol 83:476–487
Moss SE, Klein R, Klein BEK (1988) The incidence of visual loss in a diabetic population. Ophthalmology 95:1340–1348
Funatsu H, Yamashita H, Ikeda T, Mimura T, Eguchi S, Hori S (2003) Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology 110:1690–1696
Funatsu H, Yamashita H, Sakata K, Noma H, Mimura T, Suzuki M, Eguchi S, Hori S (2005) Vitreous levels of vascular endothelial growth factor and intracellular adhesion molecule 1 are related to diabetic macular edema. Ophthalmology 112:806–816
Butler JM, Guthrie SM, Koc M, Afzal A, Caballero S, Brooks HL, Mames RN, Seqal MS, Grant MB, Scott EW (2005) SDF-1 is both necessary and sufficient to promote proliferative retinopathy. J Clin Invest 115:86–93
Meleth AD, Agron F, Chan CC, Reed GF, Agora K, Byrnes G, Csaky KG, Ferris FL, Chew EY (2005) Serum inflammatory markers in diabetic retinopathy. Invest Ophthalmol Vis Sci 46:4295–4301
Fukuda M (1994) Classification and treatment of diabetic retinopathy. Diabetes Res Clin Pract 24:S171–S176
Desai TR, Leeper NJ, Hynes KL, Gewertz BL (2002) Interleukin-6 causes endothelial barrier dysfunction via the protein kinase C pathway. J Surg Res 104:118–123
Maruo N, Morita I, Shirao M, Murota S (1992) IL-6 increases endothelial permeability in vitro. Endocrinology 131:710–714
Sriramarao P, Broide DH (1996) Differential regulation of eosinophil adhesion under conditions of flow in vivo. Ann N Y Acad Sci 796:218–225
Gardner TW, Antonetti DA, Barber AJ, Lieth E, Tarbell JA (1999) The molecular structure and function of the inner blood retinal barrier. Penn State Retina Research Group. Doc Ophthalmol 97:229–237
Vinores SA, Derevjanik NL, Ozaki H, Okamoto N, Campochiaro PA (1997) Cellular mechanisms of blood-retinal barrier dysfunction in macular edema. Doc Ophthalmol 97:217–228
Itaya M, Sakurai E, Nozaki M, Yamada K, Yamasaki S, Asai K, Ogura Y (2007) Upregulation of VEGF in murine retina via monocyte recruitment after retinal scatter laser photocogulation. Invest Ophthalmol Vis Sci 48:5677–5683
Shimura M, Yasuda K, Nakazawa T, Shiono T, Nishida K (2007) Panretinal-photocoagulation before pars plana vitrectomy influences vitreous level of interleukin-6 but not of vascular endothelial growth factor in patients with diabetic retinopathy. Int J Biomed Sci 3:31–37
Shimura M, Nakazawa T, Yasuda K, Shiono T, Iida T, Sakamoto T, Nishida K (2008) Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. Am J Ophthalmol 145:854–861
Roh MI, Kim HS, Song JH, Lim JB, Kwon OW (2009) Effect of intravitreal bevacizumab injection on aqueous humor cytokine levels in clinically signifcant macular edema. Ophthalmology 116:80–86
Ho T, Smiddy WE, Flynn HWJ (1992) Vitrectomy in the management of diabetic eye disease. Surv Ophthalmol 37:190–202
McDonald HR, Schatz H (1985) Macular edema following panretinal photocoagulation. Retina 5:5–10
McDonald HR, Schatz H (1985) Visual loss following panretinal photocoagulation for proliferative diabetic retinopathy. Ophthalmology 92:388–393
Higgins KE, Meyers SM, Jaffe MJ, Roy MS, de Monasterio FM (1986) Temporary loss of foveal contrast sensitivity associated with panretinal photocoagulation. Arch Ophthalmol 104:997–1003
Henricsson M, Heiji A (1994) The effect of panretinal photocoagulation on visual acuity, visual field and on subjective visual impairment in preproliferative and early proliferative diabetic retinopathy. Acta Ophthalmol 72:570–575
Jain AT, Blumenkranz MS, Paulus Y, Wiltberger MW, Anderson DE, Huie P, Palanker D (2008) Effect of pulse duration on size and character of lesion in retinal photocoagulation. Arch Ophthalmol 126:78–85
Acknowledgement
The authors thank Dr. Norio Sugimoto in Theranostic Instruments Research Laboratories for technical support of statistical analyses and useful comments, and also thank Dr Dee Worman in Edit Science Co. Ltd for English editing.
Proprietary Interest
None
Author information
Authors and Affiliations
Corresponding author
Additional information
This study was supported by 2007 scientific grants in aid for clinical research by NTT East Japan Tohoku Hospital to MS, and 2007 scientific grant in aid by The Eye Research Foundation for the Aged to MS.
Rights and permissions
About this article
Cite this article
Shimura, M., Yasuda, K., Nakazawa, T. et al. Panretinal photocoagulation induces pro-inflammatory cytokines and macular thickening in high-risk proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 247, 1617–1624 (2009). https://doi.org/10.1007/s00417-009-1147-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00417-009-1147-x